OmniAb (OABI) Stock Price, News & Analysis

-0.09 (-1.94%)
(As of 02:28 PM ET)
Today's Range
50-Day Range
52-Week Range
145,273 shs
Average Volume
462,649 shs
Market Capitalization
$532.94 million
P/E Ratio
Dividend Yield
Price Target

OmniAb MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
97.8% Upside
$9.00 Price Target
Short Interest
Dividend Strength
News Sentiment
0.56mentions of OmniAb in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$1.17 M Bought Last Quarter
Proj. Earnings Growth
From ($0.58) to ($0.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.80 out of 5 stars

Medical Sector

399th out of 909 stocks

Commercial Physical Research Industry

7th out of 12 stocks

OABI stock logo

About OmniAb Stock (NASDAQ:OABI)

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

OABI Stock Price History

OABI Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
RBC Capital Remains a Buy on OmniAb (OABI)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Benchmark Co. Reaffirms Their Buy Rating on OmniAb (OABI)
OmniAb’s Market Potential and Financial Stability Affirm Buy Rating
Recap: OmniAb Q4 Earnings
2 Speculative Small-Cap Biotech Stocks You Should Know About
OmniAb to Participate in Two Investor Conferences in March
OmniAb Inc OABI
See More Headlines
Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Commercial physical research
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$34.16 million
Book Value
$2.69 per share


Free Float
Market Cap
$534.11 million
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Matthew W. Foehr (Age 51)
    President, CEO & Director
    Comp: $967.72k
  • Mr. Kurt A. Gustafson (Age 56)
    Executive VP of Finance & CFO
    Comp: $558.48k
  • Mr. Charles S. Berkman J.D. (Age 55)
    Chief Legal Officer & Secretary
    Comp: $734.33k
  • Ms. Cia McCaffrey
    Vice President of People & Talent
  • Dr. Bill Harriman Ph.D.
    Senior Vice President of Antibody Discovery
  • Ms. Marie-Cecile van de Lavoir D.V.M.
    Ph.D., Senior Vice President of Technical Operations & Genetics
  • Dr. Christel Iffland Ph.D.
    Senior Vice President of Antibody Technologies
  • Dr. Douglas S. Krafte Ph.D. (Age 66)
    Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head
  • Ms. Donna Ventura CPA
    Senior Vice President of Corporate Controller

OABI Stock Analysis - Frequently Asked Questions

Should I buy or sell OmniAb stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OABI shares.
View OABI analyst ratings
or view top-rated stocks.

What is OmniAb's stock price target for 2024?

4 brokerages have issued 12 month target prices for OmniAb's stock. Their OABI share price targets range from $7.00 to $11.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 97.8% from the stock's current price.
View analysts price targets for OABI
or view top-rated stocks among Wall Street analysts.

How have OABI shares performed in 2024?

OmniAb's stock was trading at $6.17 at the start of the year. Since then, OABI stock has decreased by 26.3% and is now trading at $4.55.
View the best growth stocks for 2024 here

When is OmniAb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our OABI earnings forecast

How can I listen to OmniAb's earnings call?

OmniAb will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were OmniAb's earnings last quarter?

OmniAb, Inc. (NASDAQ:OABI) issued its earnings results on Wednesday, March, 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. The company had revenue of $4.82 million for the quarter, compared to analysts' expectations of $6.94 million. OmniAb had a negative trailing twelve-month return on equity of 15.41% and a negative net margin of 148.16%.

What ETF holds OmniAb's stock?

iShares Genomics Immunology and Healthcare ETF holds 161,593 shares of OABI stock, representing 0.59% of its portfolio.

Who are OmniAb's major shareholders?

OmniAb's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rice Hall James & Associates LLC (2.25%), Woodstock Corp (0.64%), Allspring Global Investments Holdings LLC (0.07%), Mesirow Financial Investment Management Inc. (0.03%), Bfsg LLC (0.02%) and Trivant Custom Portfolio Group LLC (0.01%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr.
View institutional ownership trends

How do I buy shares of OmniAb?

Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OABI) was last updated on 4/24/2024 by Staff

From Our Partners